Holen Sie sich die Stockscreener-App
597.78
2.00%
11.71
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TMO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$586.07
Offen:
$582.2
24-Stunden-Volumen:
1.80M
Relative Volume:
0.91
Marktkapitalisierung:
$224.59B
Einnahmen:
$43.74B
Nettoeinkommen (Verlust:
$6.58B
KGV:
34.54
EPS:
17.3072
Netto-Cashflow:
$6.11B
1W Leistung:
+3.78%
1M Leistung:
+4.42%
6M Leistung:
+51.85%
1J Leistung:
+16.25%
1-Tages-Spanne:
$581.80
$602.32
1-Wochen-Bereich:
$567.21
$602.32
52-Wochen-Spanne:
$385.46
$610.97
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Firmenname
Thermo Fisher Scientific Inc
Sektor
Branche
Telefon
(781) 622-1000
Adresse
168 THIRD AVENUE, WALTHAM, MA
Vergleichen Sie TMO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
597.78 | 220.19B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
230.77 | 160.33B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
766.68 | 60.06B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
157.20 | 43.55B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
231.92 | 38.86B | 15.90B | 1.28B | 2.21B | 7.2842 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Eingeleitet | William Blair | Outperform |
| 2025-07-24 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-03-18 | Fortgesetzt | Citigroup | Neutral |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-26 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-06 | Fortgesetzt | Citigroup | Buy |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-07-19 | Bestätigt | Robert W. Baird | Outperform |
| 2023-07-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Bestätigt | Barclays | Overweight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-27 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Fortgesetzt | Barclays | Overweight |
| 2021-10-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Bestätigt | Needham | Buy |
| 2020-04-23 | Bestätigt | Needham | Buy |
| 2020-01-31 | Bestätigt | Needham | Buy |
| 2020-01-22 | Eingeleitet | Credit Suisse | Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-25 | Bestätigt | Needham | Buy |
| 2019-07-16 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-05-23 | Bestätigt | Needham | Strong Buy |
| 2019-04-22 | Bestätigt | Needham | Strong Buy |
| 2019-04-16 | Bestätigt | BofA/Merrill | Buy |
Alle ansehen
Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten
Thermo Fisher Inaugurates Customer Experience and Bioprocess Centre’s in Hyderabad - Chemical Industry Digest
Medical Precision Parts Market Research Report 2025-2030 Featuring Key PlayersGemsons, ARC, Precision Resource, Thermo Fisher Scientific, Stryker, Linamar, and TS PrototypesResearchAndMarkets.com - Business Wire
Thermo Fisher Scientific prices offering of senior notes - Medical Buyer
Competent Cells Market to Get an Explosive Growth| Thermo Fisher - openPR.com
Gene Silencing Market Is Booming Worldwide 2025-2032 | Thermo - openPR.com
Cell Culture Media Market Growing Trends and Demands Analysis - openPR.com
Thermo Fisher expands India footprint with Customer Experience, Bioprocess Design Centers at Genome... - Medical Dialogues
Thermo Fisher Scientific Prices Offering of Euro-Denominated Notes at 100% of Par Value - MarketScreener
Thermo Fisher Scientific prices €2.1B euro-denominated senior notes offering - MSN
Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes - BioSpace
Are Thermo Fisher Shares a Fair Deal After Key Pharma Partnerships and 14% Price Surge? - Yahoo Finance
Thermo Fisher prices €2.1 billion notes offering in two tranches - Investing.com
Thermo Fisher prices €2.1 billion notes offering in two tranches By Investing.com - Investing.com Australia
Thermo Fisher Scientific Subsidiary Prices EUR 2.1 Bln Senior Notes Offering - Nasdaq
Thermo Fisher (NYSE: TMO) Prices €2.1B Euro Senior and Floating-Rate Notes - Stock Titan
Thermo Fisher opens CGT collaboration center in Philadelphia - BioProcess International
Thermo Fisher launches TSQ Certis triple quadrupole mass spectrometer - rdworldonline.com
Thermo Fisher goes big with first euro bond since 2022 - GlobalCapital
Thermo Fisher Scientific sets up 2 facilities in Hyd - BusinessLine
Fitch Rates Thermo Fisher Scientific (Finance I) B.V.'s Senior Euro Notes 'A-' - TradingView
Research Antibodies Market Size, Outlook 2030 by Key Companies- - openPR.com
Thermo Fisher (NYSE:TMO) Shares Edge Higher on Sector Activity - Kalkine Media
Thermo Fisher Scientific (TMO): Assessing Valuation After FDA Wins Expand Cancer and Diagnostic Offerings - simplywall.st
Thermo Fisher Scientific Stock Prediction: Where Analysts See the Stock Going by 2027 - TIKR.com
Why Is Thermo Fisher (TMO) Up 0.2% Since Last Earnings Report? - sharewise.com
Oncology Biomarker Market Accelerates Toward USD 113.5 Billion by 2034 - GlobeNewswire Inc.
Thermo Fisher Scientific Launches Industry-First, Multi-Parameter Molecular Assay for Rapid Beverage Quality Testing* - Food Industry Executive
Genomic Biomarker Market By Top Companies Illumina,Thermo - openPR.com
Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer - BioSpace
Thermo Fisher Scientific: Assessing Value After Diagnostics Acquisition and Recent Share Price Gains - simplywall.st
Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth - The Globe and Mail
TMO Stock May Rise Post New PCR Test in Collab With Coca-Cola Partner - TradingView
Thermo Fisher Expands U.S. Cell & Gene Therapy Network with New Advanced Therapies Center in Philadelphia - Voice Of HealthCare
Can Thermo Fisher Scientific Inc. stock sustain institutional interestMarket Risk Analysis & Short-Term High Return Ideas - newser.com
The Bull Case For Thermo Fisher Scientific (TMO) Could Change Following EXENT System Clearance and New Philly Center Opening – Learn Why - Yahoo Finance
Will Thermo Fisher Scientific Inc stock outperform benchmarksSell Signal & Safe Entry Point Identification - newser.com
Will Thermo Fisher Scientific Inc. (TN8) stock sustain bullish trend into 2025Market Trend Report & Consistent Income Trade Ideas - newser.com
Is Thermo Fisher Scientific Inc. (Common Stock) (TN80) stock good for long term investingJuly 2025 Movers & Reliable Entry Point Alerts - newser.com
How Thermo Fisher Scientific Inc. (Common Stock) (TN80) stock behaves in tightening cyclesTrade Exit Summary & Safe Entry Zone Identification - newser.com
Institutions Love These 3 Companies, Should You As Well? - Finviz
Molecular Dynamics and Quantum Calculations: AAPS Thermo Fisher Interview, Part Two - PharmTech.com
Will Thermo Fisher Scientific Inc. (Common Stock) (TN80) stock hit analyst forecastsTrade Entry Report & Fast Moving Trade Plans - newser.com
Thermo Fisher unveils Advanced Therapies Collaboration Centre in US - BioSpectrum Asia
Thermo Fisher Scientific Launches Industry-First, Multi-Parameter Molecular Assay for Rapid Beverage Quality Testing - Morningstar
Why Thermo Fisher Scientific Inc. (Common Stock) (TN80) stock signals breakout potential2025 Analyst Calls & AI Driven Stock Reports - newser.com
Is Thermo Fisher Scientific Inc. (TN8) stock expanding market penetration2025 Market Outlook & Safe Capital Growth Tips - newser.com
What Thermo Fisher Scientific (TMO)'s FDA Clearance for EXENT System Means for Shareholders - simplywall.st
How robust is Thermo Fisher Scientific Inc stock financial positionBreakout Watch & Advanced Swing Trade Entry Plans - newser.com
Is Thermo Fisher Scientific Inc stock supported by strong fundamentalsJuly 2025 PostEarnings & Precise Buy Zone Identification - newser.com
Thermo Fisher Scientific Opens East Coast Collaboration Center at BioLabs for Advanced Therapeutics to Help Accelerate Cell and Gene Therapy Development - BioSpace
Is Thermo Fisher Scientific Inc. (TN8) stock among top earnings playsJuly 2025 Gainers & Pattern Based Trade Signal System - newser.com
Finanzdaten der Thermo Fisher Scientific Inc-Aktie (TMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):